IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: billkirn who wrote (1371)	6/3/1999 4:34:00 AM
From: billkirn	Read Replies (2) of 1510

What Peter Johnson believes is important: ''We believe the improved control of viral load observed in the clinical endpoint study provides strong support for new pivotal clinical trials of REMUNE to be based on virologic markers,'' said Peter Johnson, Agouron's president and chief executive officer. ''Concluding the clinical endpoint trial at this time also presents a unique opportunity to address a very contemporary question: can immune-based therapy extend the duration of the anti-HIV response induced by HAART under the most challenging conditions? The potential to produce this effect remains one of REMUNE's most important attributes.'' If it does IMNR is a big winner. Bill

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next